CEI Weekly: Is There a Future for Generic Biotech Crops?

Friday, September 28, 2012



Feature: A new CEI study looks at the effect of regulatory policy on crop biotechnology.

FEATURE: Is There a Future For Generic Biotech Crops?


Usually when patents expire, new generic markets are allowed to develop. But in the case of crop biotechnology, current U.S. regulatory policy could prevent a market of affordable generic biotech seeds. CEI Senior Fellow Greg Conko explains the situation and proposes regulatory reforms in a new CEI Issue Analysis: "Is There a a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry."





The Federal Department of Higher Spending and Higher Local Taxes

David Bier's op-ed in The Washington Examiner


What Do The War on Cancer and Climate Modeling Have in Common?

Bill Frezza's op-ed in Forbes


Field of Cash: If You Offer, They Will Take

Trey Kovacs' op-ed in The Daily Caller


Chicago Strike Shows Unions Corrupt Teachers, Harm Students 

Matt Patterson's op-ed in The Washington Examiner 


Unions Stack the Deck Against Job Creation

Matt Patterson & Crissy Brown's op-ed in The Washington Times


Market Demand Knocks Down Regulatory Barriers in Kansas City Fiber Deployment

Fred Campbell's op-ed in Ars Technica


'Bipartisan' Board Donates to Dems Overwhelmingly

John Berlau's citation in The Washington Free Beacon


Privacy Bill Requires Search Warrants for Email, Cell Phone Tracking

Ryan Radia's citation in CNET


PBS Newshour Omits Obama's Support for Blasphemy Law

Hans Bader's citation on HotAir
















September 27, 2012: The Future of Generic Biotech Crops


Senior Fellow Greg Conko discusses his newpaper, “Is There a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry.” Patents will soon expire for several popular biotech crops, opening the way for cheaper generic versions. But because, unlike prescription drugs, biotech crops have to be re-approved every few years, the future of generic biotech crops is very much in doubt. Conko recommends getting rid of re-approval requirements to put them on the same footing as other products.